VItiligo RegisTry adUlts And chiLdren-France
NCT07927699, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | VItiligo RegisTry adUlts And chiLdren-France | ClinicalTrials.gov |
| NCT number | NCT07927699 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 100 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris | ClinicalTrials.gov |
| Conditions | Vitiligo | ClinicalTrials.gov |
| Interventions | Vitiligo treatments in routine clinical practice | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Clinical course of vitiligo under treatment assessed by T-VASI | Baseline, 6 months, 1 year, and 2 years | Clinical course and disease severity in patients receiving currently used treatments for vitiligo, including combination therapies, will be assessed using the Total Vitiligo Area Severity Index (T-VASI). This assessment will be used to monitor changes in vitiligo severity during treatment | ClinicalTrials.gov |
| Primary | Clinical course of vitiligo under treatment assessed by sIGA | Baseline, 6 months, 1 year, and 2 years | Clinical course and disease severity in patients receiving currently used treatments for vitiligo, including combination therapies, will be assessed using the Investigator Global Assessment (sIGA). This assessment will be used to monitor changes in vitiligo severity during treatment | ClinicalTrials.gov |
| Secondary | Descriptive data of BMI | Baseline | Descriptive data of BMI will be done using mean and median. | ClinicalTrials.gov |
| Secondary | Treatment-related adverse events | Baseline, 6 months, 1 year, and 2 years | Adverse events occurring in patients receiving currently used treatments for vitiligo, including combination therapies. | ClinicalTrials.gov |
| Secondary | Measure of the quality of life | Baseline, 1 year, and 2 years | EQ-5D for adults participants. | ClinicalTrials.gov |
| Secondary | Vitiligo burden | Baseline, 6 months, 1 year, and 2 years | Vitiligo burden will be assessed using the Vitiligo Impact Patient scale (VIPs). | ClinicalTrials.gov |
| Secondary | Change in vitiligo disease activity assessed by the Vitiligo Signs of Activity Score (VSAS) | Baseline, 6 months, 1 year, and 2 years | Vitiligo disease activity will be assessed using the Vitiligo Signs of Activity Score (VSAS). Changes in VSAS scores will be monitored over time to evaluate disease activity during follow-up. | ClinicalTrials.gov |
| Secondary | Patient Self-reported Vitiligo extent (SA-VES) | Baseline, 6 months, 1 year, and 2 years | Patients self-reported of disease extent will be assessed by the Self-Assessment Vitiligo Extent Score (SA-VES).This assessment will be used to monitor changes in the extent of vitiligo over time | ClinicalTrials.gov |
| Secondary | Feasibility of the multicenter vitiligo registry | Through study completion, up to 5 years | Number of participants enrolled, missing data, and participants lost to follow-up. | ClinicalTrials.gov |
| Secondary | Measure of the quality of life | Baseline, 1 year, and 2 years | Child DLQI for pediatric participants. | ClinicalTrials.gov |
| Secondary | Age of participants at enrollment | Baseline | Age of participants at enrollment will be recorded in years and summarized using descriptive statistics. | ClinicalTrials.gov |
| Secondary | Distribution of participants by sex | Baseline | The number and percentage of participants in each recorded sex category will be reported. | ClinicalTrials.gov |
| Secondary | Number of participants with comorbidities | Baseline, 1 year, and 2 years | The number and percentage of participants with at least one recorded comorbidity will be reported. | ClinicalTrials.gov |
| Secondary | Number of participants with previous treatments for vitiligo | Baseline | The number and percentage of participants who received treatment for vitiligo prior to enrollment will be reported. | ClinicalTrials.gov |
| Secondary | Number of participants with a history of cancer | Baseline, 1 year, and 2 years | The number and percentage of participants with a recorded diagnosis of cancer, including skin cancer, will be reported. | ClinicalTrials.gov |
| Secondary | F-VASI - Facial extent of vitiligo | Baseline, 6 months, 1 year, and 2 years | Facial vitiligo severity will be assessed using the Facial Vitiligo Area Severity Index (F-VASI). This assessment will be used to monitor changes in facial vitiligo severity over time | ClinicalTrials.gov |
| Secondary | VNS - Patient reported Vitiligo noticeability scale (VNS) | Baseline, 6 months, 1 year, and 2 years | Vitiligo noticeability will be assessed using the Vitiligo Noticeability Scale (VNS). This assessment will be used to monitor changes in the perceived noticeability of vitiligo over time | ClinicalTrials.gov |
| Secondary | PHQ-4 - Patient Health Questionnaire to measure Psychological distress | Baseline, 6 months, 1 year, and 2 years | Psychological distress will be assessed using the Patient Health Questionnaire-4 (PHQ-4). Changes in PHQ-4 scores will be monitored over time to evaluate psychological distress during follow-up | ClinicalTrials.gov |
| Secondary | GAD-7 - Anxiety assessment | Baseline, 6 months, 1 year, and 2 years | Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 (GAD-7). Changes in GAD-7 scores will be monitored over time to evaluate anxiety symptoms during follow-up | ClinicalTrials.gov |
| Secondary | PUSH-D - Stigma linked to vitiligo | Baseline, 6 months, 1 year, and 2 years | Perceived and enacted stigma of vitiligo changes will be assessed using the PUSH-D questionnaire. Changes in PUSH-D scores will be monitored over time during follow-up | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)